- Home
- PLBC vs MREO Comparison
PLBC vs MREO Comparison
Compare PLBC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLBC
- MREO
- Stock Information
- Founded
- PLBC 1980
- MREO 2015
- Country
- PLBC United States
- MREO United Kingdom
- Employees
- PLBC N/A
- MREO N/A
- Industry
- PLBC Finance Companies
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PLBC Finance
- MREO Health Care
- Exchange
- PLBC Nasdaq
- MREO Nasdaq
- Market Cap
- PLBC 288.9M
- MREO 311.8M
- IPO Year
- PLBC 2005
- MREO N/A
- Fundamental
- Price
- PLBC $43.50
- MREO $1.77
- Analyst Decision
- PLBC Buy
- MREO Strong Buy
- Analyst Count
- PLBC 4
- MREO 5
- Target Price
- PLBC $56.25
- MREO $7.40
- AVG Volume (30 Days)
- PLBC 10.4K
- MREO 1.6M
- Earning Date
- PLBC 10-15-2025
- MREO 11-10-2025
- Dividend Yield
- PLBC 2.81%
- MREO N/A
- EPS Growth
- PLBC N/A
- MREO N/A
- EPS
- PLBC 4.23
- MREO N/A
- Revenue
- PLBC $89,868,000.00
- MREO $500,000.00
- Revenue This Year
- PLBC $21.11
- MREO N/A
- Revenue Next Year
- PLBC $16.11
- MREO $72.16
- P/E Ratio
- PLBC $10.10
- MREO N/A
- Revenue Growth
- PLBC 12.51
- MREO N/A
- 52 Week Low
- PLBC $38.71
- MREO $1.47
- 52 Week High
- PLBC $51.33
- MREO $4.21
- Technical
- Relative Strength Index (RSI)
- PLBC 58.18
- MREO 42.90
- Support Level
- PLBC $40.35
- MREO $1.65
- Resistance Level
- PLBC $43.50
- MREO $1.93
- Average True Range (ATR)
- PLBC 0.63
- MREO 0.12
- MACD
- PLBC 0.22
- MREO -0.02
- Stochastic Oscillator
- PLBC 72.85
- MREO 29.00
About PLBC Plumas Bancorp
Plumas Bancorp provides various banking products and services in Northeastern California and Northwestern Nevada. It provides various deposit products such as checking, interest-bearing checking, business sweep, public funds sweep, savings, time deposit, and retirement accounts. The bank's loan portfolio consists of commercial real estate loans; commercial and industrial loans; consumer loans; agricultural loans; residential real estate loans, and construction and land development loans. The bank generates revenue from loans and investment securities in its portfolio and, to a lesser extent, service fees.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).